<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3303">
  <stage>Registered</stage>
  <submitdate>20/09/2011</submitdate>
  <approvaldate>20/09/2011</approvaldate>
  <nctid>NCT01438944</nctid>
  <trial_identification>
    <studytitle>Evaluation of Transdermal Nicotine Replacement Therapy (NRT) Activity Through Metabolic Induction</studytitle>
    <scientifictitle>Evaluation of Nicotine Receptor Up-regulation Activity Through Metabolic Induction and Changes in Responsiveness Using Surrogate Evaluation Methods</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011039</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Smoking</healthcondition>
    <healthcondition>Addiction</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Nicabate 21mg transdermal NRT

Other: Nicabate 21mg transdermal NRT - 21mg Transdermal NRT applied for 24hrs over a 14day period.


Treatment: drugs: Nicabate 21mg transdermal NRT
Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline Nicotine, cotinine, Leptin and orexin Metabolite ratios - Baseline Prior to Transdermal NRT patch application Day 4 NRT Patch Application Day 14 Last Day NRT Patch Application Day 28 14 Days post NRT patch removal.</outcome>
      <timepoint>Baseline, Day 4, Day 14 and Day 28</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline Patient Instruments: Fagerstrom Test for Nicotine Dependence (FTND), Wisconsin Smoking Withdrawal Scale (WSWS), Michigan Nicotine Reinforcement Questionnaire (MNRQ), Smoker Diary - Comparative evaluation patient instruments with ratios of metabolite induction</outcome>
      <timepoint>Baseline, Day 14 and Day 28</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Smokers who currently smoke at least 10 cigarettes per day

          -  Aged between 18 and 75

          -  Informed consent

          -  Willingness to attempt to quit smoking for the period specified, initially with a
             transdermal patch for 14 days and then without any smoking cessation aids for a
             further 14 days.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Use of bupropion, champix or nicotine containing products other than cigarettes in the
             last 2 months

          -  previous reactions to NRT

          -  Pregnancy / Breast Feeding

          -  Uncontrolled hypertension

          -  Unstable angina

          -  Heart attack or stroke within the previous 6 months

          -  Severe Obesity as indicated by Body Mass Index (BMI) =35 (potential for slow release
             of nicotine from tissues)

          -  acute psychiatric illness, past history psychosis, suicidal ideation or current
             diminished capacity.

          -  Current treatment or recent diagnosis of cancer

          -  Current use of Phenobarbital or other anticonvulsant drugs (induction of metabolism of
             nicotine to cotinine)

          -  Renal failure (creatinine clearance&lt;30ml/min - reduces metabolic clearance of cotinine
             and nicotine)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Health Services Research</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>52</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Kristin Carson - Adelaide</hospital>
    <postcode>5044 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The Queen Elizabeth Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Basil Hetzel Institute for Translational Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Adelaide</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of South Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Clinical Practice Unit</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Therapeutics Research Centre</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Evaluation to determine if auto-induction can be used as a surrogate measure of nicotine
      receptor up-regulation through an observational study using nicotine replacement therapy for
      two weeks and no intervention for two weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01438944</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael Roberts, BPharm PhD</name>
      <address>University of Queeensland, University of South Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>